Jingyi Li
Shanghai Jiao Tong University
3 Papers
3 Citations
Jingyi Li is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Cell growth & Protein kinase B. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells
Lanlan Liu,Lanlan Liu,Zhaojuan Yang,Yingqian Xu,Jingyi Li,Dongxu Xu,Li Zhang,Jiabin Sun,Suhua Xia,Fei-yan Zou,Yongzhong Liu +10 more
TL;DR: It is found that PPARγ agonists inhibited the cancer stem cell-like phenotype and attenuated tumor growth of human hepatocellular carcinoma (HCC) cells and a negative feedback loop between oxidative stress and AKT hyperactivation in PParγ agonist-mediated suppressive effects on HCCs is observed.
Myeloid TGF-β signaling contributes to colitis-associated tumorigenesis in mice
Jingyi Li,Yun Liu,Boshi Wang,Yingqian Xu,Aihui Ma,Feng Zhang,Chao Ge,Zhaojuan Yang,Jinjun Li,Yongzhong Liu +9 more
TL;DR: It is demonstrated that transforming growth factor-β (TGF-β) signaling in colonic myeloid cells is significantly involved in the development of CAC and modulates intestinal inflammation and significantly promotes tumorigenesis in theDevelopment of colitis-associated colon cancer.
16
c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells.
Yulan Qu,Li Zhang,Aihui Ma,Feng Zhang,Jingyi Li,Dongxu Xu,Zhaojuan Yang,Wenxin Qin,Wenxin Qin,Yongzhong Liu +9 more
TL;DR: The results provide evidence that TAK1-dependency in the tumorigenicity of AKT-transformed cells can be alleviated by c-Myc overexpression, and suggest that dual-targeting Tak1 and c- myc might be a rational therapeutic strategy for treatment of certain types of cancer.
3